Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common gout drug shield the liver from cirrhosis complications?

NCT ID NCT07800598

Prevention Sponsor: Bangladesh Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether allopurinol, a drug usually used for gout, can prevent serious complications in people with decompensated cirrhosis, a late stage of liver disease. Researchers will give 54 adults with Child-Pugh B or C cirrhosis either allopurinol or a placebo for six months, alongside standard care. The goal is to see if allopurinol reduces events like fluid buildup, bleeding, and kidney failure, and improves liver function scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
allopurinol tablet
What this could lead to
If it works, allopurinol could become a low-cost, widely available way to prevent life-threatening complications in people with advanced cirrhosis.
What could go wrong
This is a small, early-phase trial with only 54 participants, so results may not apply broadly. Allopurinol can cause allergic reactions and is not safe for people with severe kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adult patients (age : 18-70 years) diagnosed with Decompensated cirrhosis of liver with any etiology of cirrhosis . * CTP score B or C . Exclusion Criteria: * • Patients with known hypersensitivity or allergy to allopurinol. * Patients with active HE or SBP or HRS-AKI or a history of any of these events within the last 4 weeks. * Patients with advanced renal impairment (e.g., creatinine clearance \<30 mL/min). * Pregnant or breastfeeding women. * Patients with severe comorbidities (e.g., uncontrolled cardiovascular disease, cancer, or severe infections). * Patients currently using medications that interact with allopurinol (e.g., azathioprine, mercaptopurine, Cyclophosphamide, Thiazide diuretics ,Warfarin, Theophyllin ).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhoses, liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhoses, liver Decompensated cirrhosis of liver

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Hepatology at Bangladesh Medical University.

    RECRUITING

    Dhaka, Shahbagh, 1100, Bangladesh

  • Department of Hepatology at Bangladesh Medical University.

    RECRUITING

    Dhaka, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.